Replies to post #175242 on Biotech Values

[honestabe13]

got that right.

PPHM has numerous presentations this week surrounding early-stage clinical trials in a variety of cancers with bavituximab in combination with approved treatments, where they will claim to show significant improvements over the approved treatments alone. either it will be well-received and boost the share price, or it will be ignored.

i can certainly say with confidence that, even if it's well received in the scientific and financial communities, it will be trashed here :)